Efficacy and tolerability of AP 5346 in patients with recurrent, platinum-resistant ovarian cancer

Trial Profile

Efficacy and tolerability of AP 5346 in patients with recurrent, platinum-resistant ovarian cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2010

At a glance

  • Drugs AP 5346 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jan 2010 Status changed from recruiting to completed, as reported in an Access Pharmaceuticals media release.
    • 05 Mar 2009 Results reported in a Access Pharmaceuticals media release.
    • 21 Oct 2008 Results presented at the Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top